Ph.D. Supervisor, Researcher (Professional and technical second-level posts), Chief Physician. Graduated with a Ph.D. in Surgery from Harbin Medical University in 2011. Recognized as National Young Talent Program, the fifth batch of Anhui Special Support Program Leading Talents in Science and Technology Innovation, the winner of the Outstanding Youth Fund of the Anhui Provincial Natural Science Foundation, the winner of the special allowance of Anhui Province, the twelfth batch of reserve candidates for academic and technical leaders in Anhui Province, the leading talents introduced by medicine in Anhui Province, and the outstanding young graduate tutor in Anhui Province. Conducted over two years of oncology research at the Cancer Institute of New Jersey (CINJ) as a visiting scholar and postdoctoral fellow. Published over 30 academic papers as first or corresponding author in journals such as Hepatology、Journal of Hepatology、GUT、Nature Communications、Clinical Cancer Research.Awarded the first prize of Natural Science of the Ministry of Education, the first prize of Scientific and Technological Progress of the Ministry of Education and the first prize of Heilongjiang Provincial Government.
Education and Work Experience
- September 1999 – June 2004: Bachelor’s in Clinical Medicine, Harbin Medical University
- September 2005 – June 2008: Master’s in Surgery, Harbin Medical University
- September 2008 – June 2011: Ph.D. in Surgery, Harbin Medical University
Academic Achievements and Impact
Focused on surgical education and clinical research in digestive system tumors, with a primary interest in molecular targeted therapy for hepatobiliary tumors. Published 30 SCI-indexed papers as first or corresponding author in journals such as Hepatology, Journal of Hepatology, GUT, Nature Communications, and Clinical Cancer Research, with over 1000 citations and the highest single paper cited 218 times.
Ongoing Projects (Principal Investigator Only)
- Study on the Mechanism of CKAP2L/NF-kB Signaling Pathway Facilitating the Occurrence and Development of Hepatocellular Carcinoma
- Total Funding: 5.2 million CNY
- Duration: 2023-01 to 2026-12
Main Research Directions (Enrollment Specialties) and Content
Biology
1. Cell Biology
- Functional mechanisms of long non-coding RNA in the development of hepatobiliary tumors
- Immune evasion mechanisms of hepatobiliary tumor cells
- Amino acid and lipid metabolism reprogramming in hepatobiliary tumor cells
- Inflammation-related pathways in hepatobiliary tumor cells
Clinical Medicine
1. Surgery
- Molecular targeted therapy research for hepatobiliary tumors
- Mechanisms of drug resistance and reversal in hepatobiliary tumors
- Early screening and diagnosis of hepatobiliary tumors
Representative Papers (Last Five Years)
1. Sun L, Liu Y, Guo X, Cui T, Wu C, Tao J, Cheng C, Chu Q, Ji C, Li X, Guo H, Liang S, Zhou H, Zhou S, Ma K, Zhang N, Wang J, Liu Y, Liu L. Acetylation-dependent regulation of core spliceosome modulates hepatocellular carcinoma cassette exons and sensitivity to PARP inhibitors. Nat Commun. 2024 Jun 18;15(1):5209.（Corresponding author）
2. Li X, Liang S, Fei M, Ma K, Sun L, Liu Y, Liu L, Wang J. LncRNA CRNDE Drives the Progression of Hepatocellular Carcinoma by inducing the Immunosuppressive Niche. Int J Biol Sci. 2024 Jan 1;20(2):718-732.（Corresponding author）
3. Fei M, Li X, Liang S, Zhou S, Wu H, Sun L, Liu Y, Hu Q, Liu L, Wang J. LncRNA PWRN1 inhibits the progression of hepatocellular carcinoma by activating PKM2 activity. Cancer Lett. 2024 Mar 1;584:216620.（Corresponding author）
4. Liu Y, Xun Z, Ma K, Liang S, Li X, Zhou S, Sun L, Liu Y, Du Y, Guo X, Cui T, Zhou H, Wang J, Yin D, Song R, Zhang S, Cai W, Meng F, Guo H, Zhang B, Yang D, Bao R, Hu Q, Wang J, Ye Y, Liu L. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol. 2023 Apr;78(4):770-782.( Corresponding author)
5. Zheng C, Zhang B, Li Y, Liu K, Wei W, Liang S, Guo H, Ma K, Liu Y, Wang J, Liu L. Donafenib and GSK-J4 Synergistically Induce Ferroptosis in Liver Cancer by Upregulating HMOX1 Expression. Adv Sci (Weinh). 2023 Aug;10(22):e2206798. （Corresponding author）
6. Liu Y, Sun L, Guo H, Zhou S, Wang C, Ji C, Meng F, Liang S, Zhang B, Yuan Y, Ma K, Li X, Guo X, Cui T, Zhang N, Wang J, Liu Y, Liu L. Targeting SLP2-mediated lipid metabolism reprograming restricts proliferation and metastasis of hepatocellular carcinoma and promotes sensitivity to Lenvatinib. Oncogene. 2023 Jan;42(5):374-388. （Corresponding author）
7. Li H, Liu Y, Cheng C, Wu Y, Liang SH, Wu L, Wang H, Tu CY, Yao HH, Meng FZ, Zhang B, Wang W, Wang JB, Liu LX. UBE2O reduces the effectiveness of interferon-α via degradation of IFIT3 in hepatocellular carcinoma. Cell Death Dis. 2023 Dec 21;14(12):854.（Corresponding author）
Contact Information
E-mail: jbwang16@ustc.edu.cn
Phone: 0551-62284121